BridgeBio Oncology (BBOT) director receives 31,675-share stock option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics director Frank McCormick received a new stock option grant. He was awarded options for 31,675 shares of common stock at an exercise price of $7.73 per share. These options were granted at no upfront cost and are held as a direct ownership position.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues serving the company through that date. Following this grant, his reported derivative holdings from this award total 31,675 underlying shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
MCCORMICK FRANK
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 31,675 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 31,675 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 31,675 shares
Exercise price: $7.73 per share
Total derivative shares after grant: 31,675 shares
+1 more
4 metrics
Option grant size
31,675 shares
Stock Option (Right to Buy) grant to director on 2026-06-16
Exercise price
$7.73 per share
Conversion or exercise price of the stock option
Total derivative shares after grant
31,675 shares
Total shares following transaction for this option award
Option expiration
2036-06-15
Expiration date of the stock option grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, Annual Meeting of Stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 7.7300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares underlying the stock option vest in full upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did BridgeBio Oncology Therapeutics (BBOT) report for Frank McCormick?
BridgeBio Oncology Therapeutics reported that director Frank McCormick received a stock option grant for 31,675 shares. The options relate to common stock and were awarded as compensation rather than an open-market purchase, reflecting routine equity-based director pay.
How many BridgeBio Oncology Therapeutics (BBOT) options were granted and at what price?
Frank McCormick was granted stock options covering 31,675 shares of BridgeBio Oncology Therapeutics common stock. The options have an exercise price of $7.73 per share, meaning he can buy shares at that price once the options vest, subject to the vesting conditions.
When do Frank McCormick’s BBOT stock options vest according to the Form 4?
The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. Vesting is contingent on Frank McCormick’s continued service to BridgeBio Oncology Therapeutics through the applicable vesting date, as disclosed.
Is Frank McCormick’s BBOT option grant an open-market buy or a compensation award?
The transaction is a compensation-related award, not an open-market purchase. The Form 4 labels it as a grant or award acquisition with a transaction code A, covering 31,675 stock options granted at a $7.73 exercise price, issued at no upfront share purchase cost.
What is Frank McCormick’s reported position after this BBOT option grant?
After the grant, Frank McCormick’s reported derivative holdings from this award total 31,675 underlying shares. The Form 4 shows total shares following the transaction of 31,675 tied to this stock option, reflecting his newly granted but vesting-dependent equity exposure.